RGLS - Regulus Therapeutics Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.5900
+0.0087 (+1.50%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.5813
Open0.5825
Bid0.5700 x 900
Ask0.7500 x 900
Day's Range0.5715 - 0.5996
52 Week Range0.5000 - 3.8400
Volume23,094
Avg. Volume163,289
Market Cap12.287M
Beta (3Y Monthly)1.49
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Regulus Therapeutics Reports Second Quarter 2019 Financial Results and Recent Updates
    PR Newswire

    Regulus Therapeutics Reports Second Quarter 2019 Financial Results and Recent Updates

    Private Financing: In May 2019, the Company closed the first tranche of its $41.8 million private placement of equity (the "Private Placement"). The Company received net proceeds of approximately $15.7 million from the first tranche, after deducting placement agent fees and other offering expenses.

  • Regulus Therapeutics Appoints Cris Calsada as Chief Financial Officer
    PR Newswire

    Regulus Therapeutics Appoints Cris Calsada as Chief Financial Officer

    LA JOLLA, Calif., July 30, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the appointment of Cris Calsada as its new Chief Financial Officer effective August 30, 2019. Ms. Calsada joins Regulus from Sanifit where she has served as Chief Financial Officer since December 2017.  Ms. Calsada brings to Regulus' senior management team a unique combination of financial, operational and managerial experience. Earlier in her career, she practiced as a certified public accountant.

  • Regulus Therapeutics Announces RGLS4326 Program Update
    PR Newswire

    Regulus Therapeutics Announces RGLS4326 Program Update

    LA JOLLA, Calif., July 23, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced a program update for RGLS4326 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). The Company has been working with the United States Food and Drug Administration (FDA) since July 2018, when Regulus voluntarily paused the Phase 1 clinical program due to unexpected findings in the mouse chronic toxicity study being run in parallel with the Phase 1 program.  In consultation with FDA, Regulus provided the interim analyses from a new mouse chronic toxicity study and the non-human primate (NHP) chronic toxicity study and supporting information to enable re-initiation of the Multiple Ascending Dose (MAD) study.

  • Regulus Announces New Additions to Board of Directors
    PR Newswire

    Regulus Announces New Additions to Board of Directors

    Concurrently with their appointments to the Board, Mr. Nunn was appointed to serve on the Audit Committee and Dr. Simeonidis was appointed to serve on the Corporate Governance & Nominating Committee. Mr. Nunn is a venture advisor at New Enterprise Associates (NEA) and Dr. Simeonidis is a partner with Sarissa Capital.  Both NEA and Sarissa Capital participated in the Company's previously announced $41.8 million private placement of equity.

  • Regulus Therapeutics Reports First Quarter 2019 Financial Results and Recent Updates
    PR Newswire

    Regulus Therapeutics Reports First Quarter 2019 Financial Results and Recent Updates

    "I am proud of the significant progress we have made thus far in 2019 to reposition Regulus with a strengthened balance sheet, restructured term loan and reduced operating cash burn rate.  Importantly, the team has maintained its focus in its engagement with FDA, and we look forward to resuming our ADPKD clinical program pending FDA alignment.  We believe the total potential proceeds from the recent financing, highlighted by a strong investor syndicate, provides sufficient capital to fund planned activities into the second half of 2021," said Jay Hagan, CEO of Regulus. Private Financing: In May 2019, the Company closed the first tranche of its $41.8 million private placement of equity (the "Private Placement").

  • Regulus Therapeutics Announces Closing of First Tranche of $41.8 Million Private Placement of Equity
    PR Newswire

    Regulus Therapeutics Announces Closing of First Tranche of $41.8 Million Private Placement of Equity

    LA JOLLA, Calif. , May 7, 2019 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, ...

  • Regulus Therapeutics Announces Restructuring of Term Loan
    PR Newswire

    Regulus Therapeutics Announces Restructuring of Term Loan

    LA JOLLA, Calif., May 6, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it has entered into an amendment (the "Amendment") with Oxford Finance LLC. The Amendment to the Term Loan, with a principal balance outstanding of $14.7 million, provides the Company with a new twelve-month period of interest-only payments, commencing May 2019 and a two-year extension of its maturity date to May 2022. Upon the closing of the second tranche of the Company's recently announced private financing, the Company will receive an additional twelve-month period of interest-only payments, commencing May 2020.

  • Regulus Therapeutics Announces Private Placement of Equity
    PR Newswire

    Regulus Therapeutics Announces Private Placement of Equity

    LA JOLLA, Calif., May 6, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it has entered into a definitive securities purchase agreement with certain institutional and other accredited investors for aggregate gross proceeds of up to approximately $41.8 million in a two-tranche private placement of equity.  The initial tranche of approximately $16.7 million, priced at the market, is anticipated to close on or about May 7, 2019, subject to the satisfaction of customary closing conditions. Under the securities purchase agreement the investors have agreed to purchase, at an initial closing, approximately 9.7 million shares of the Company's Common Stock ("Common Stock") and accompanying warrants to purchase up to an aggregate of approximately 9.7 million shares of Common Stock, at a combined purchase price of $1.205 per share and accompanying warrant.

  • Regulus to Present Preclinical Efficacy Data Highlighting Potential of Novel Treatment for Nonalcoholic Steatohepatitis at The International Liver Congress™ 2019
    PR Newswire

    Regulus to Present Preclinical Efficacy Data Highlighting Potential of Novel Treatment for Nonalcoholic Steatohepatitis at The International Liver Congress™ 2019

    "We are pleased to be presenting preclinical data during this year's EASL International Liver Congress that we believe demonstrates the potential of our lead anti-miR-132 to be a promising therapeutic for the treatment of NASH," said Jay Hagan, President and Chief Executive Officer of Regulus. Details of the late breaker poster presentation are as follows and will be available for download at the time of presentation at http://regulusrx.com/publications.

  • ACCESSWIRE

    Four Healthcare Stocks Getting a Boost on Thursday

    CORAL GABLES, FL / ACCESSWIRE / March 28, 2019 / The healthcare stock market has been a hotbed of excitement in the first few months of 2019 as companies in the industry have focused their efforts on developing innovative technologies and treatments for consumers. Consumers depend and expect healthcare companies to invest in new forms of drug treatments and other aspects of the care experience so that, when a patient needs care, they don't have to look very far. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Arcturus Therapeutics Ltd (ARCT), Sesen Bio Inc (SESN), and Regulus Therapeutics Inc (RGLS) are 4 healthcare companies making moves on Thursday.

  • Regulus Reports Fourth Quarter and Year-End 2018 Financial Results and Recent Updates
    PR Newswire

    Regulus Reports Fourth Quarter and Year-End 2018 Financial Results and Recent Updates

    LA JOLLA, Calif. , March 18, 2019 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, ...

  • Regulus Announces Transition of Research Leadership
    PR Newswire

    Regulus Announces Transition of Research Leadership

    LA JOLLA, Calif., March 15, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the resignation of Dr. Timothy Wright, Chief Research and Development Officer, effective March 15, 2019.  Dr. Wright is leaving for personal reasons to pursue a new opportunity, and will continue to support Regulus as a scientific advisor.

  • Regulus Announces Clinical Candidate Nomination for the Treatment of Glioblastoma Multiforme
    PR Newswire

    Regulus Announces Clinical Candidate Nomination for the Treatment of Glioblastoma Multiforme

    Standard of care temozolomide as a single agent increased median survival by 27% vs. control, therefore the combination of RGLS5579 plus temozolomide demonstrated synergistic efficacy in this model. RGLS5579 has completed the clinical candidate screening process demonstrating appropriate preliminary safety and drug-like properties.

  • Regulus Announces Preliminary Results of Planned Interim Data Analysis of RGLS4326 in New Mouse Chronic Toxicity Study
    PR Newswire

    Regulus Announces Preliminary Results of Planned Interim Data Analysis of RGLS4326 in New Mouse Chronic Toxicity Study

    LA JOLLA, Calif., Jan. 4, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the preliminary results of a planned interim data analysis from the new mouse chronic toxicity study of RGLS4326 in development for the treatment of Autosomal Dominant Polycystic Kidney Disease, or ADPKD. As previously reported by the Company in July 2018, and in consultation with FDA, the Company voluntarily paused its ongoing Phase 1 Multiple Ascending Dose ("MAD") study of RGLS4326 in healthy volunteers due to unexpected observations in the 27-week mouse chronic toxicity study.  The Company terminated that mouse study prematurely at week 14.  The study was run in parallel to the Phase 1 program to enable initiation of the Phase 2 program in ADPKD patients upon completion of the Phase 1 MAD study.

  • GlobeNewswire

    Research Report Identifies Advanced Energy Industries, Altair Engineering, Rambus, Regulus Therapeutics, NN, and Halcon Resources with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Regulus Presents Preclinical Survival Data Highlighting Potential of Novel Treatment for Glioblastoma Multiforme
    PR Newswire

    Regulus Presents Preclinical Survival Data Highlighting Potential of Novel Treatment for Glioblastoma Multiforme

    Single Dose of Lead anti-miR-10b Compound in Combination with temozolomide Resulted in over 150% Increase in Median Survival LA JOLLA, Calif. , Nov. 19, 2018 /PRNewswire/ --  Regulus Therapeutics Inc . ...

  • Regulus Reports Third Quarter 2018 Financial Results and Recent Updates
    PR Newswire

    Regulus Reports Third Quarter 2018 Financial Results and Recent Updates

    $47 Million Restructured Sanofi Collaboration Executed Initiated New Chronic Mouse Toxicity Study for RGLS4326; Data Anticipated in Q1 2019 LA JOLLA, Calif. , Nov. 8, 2018 /PRNewswire/ --  Regulus Therapeutics ...

  • Regulus Announces Successful Restructuring of Sanofi Collaboration
    PR Newswire

    Regulus Announces Successful Restructuring of Sanofi Collaboration

    Sanofi Will Assume Development of RG-012 for Alport syndrome LA JOLLA, Calif. , Nov. 6, 2018 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery ...

  • Regulus to Present Data from ATHENA, a Global Natural History of Disease Study for Alport Syndrome, at ASN's Kidney Week 2018
    PR Newswire

    Regulus to Present Data from ATHENA, a Global Natural History of Disease Study for Alport Syndrome, at ASN's Kidney Week 2018

    LA JOLLA, Calif. , Oct. 25, 2018 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, ...

  • ACCESSWIRE

    3 Healthcare Stocks To Watch On Tuesday

    Healthcare stocks have helped during times like these. Three healthcare stocks to watch this week include Premier Health Group, Inc. (PHGRF)(PHGI.CN), Neovasc Inc. (NVCN), and Regulus Therapeutics Inc. (RGLS). Premier Health Group, Inc. (PHGRF)(PHGI.CN), continued to trade higher this week.

  • Regulus to Present Preclinical Data Supporting RGLS4326 as a Novel Therapeutic in Development for Autosomal Dominant Polycystic Kidney Disease at ASN's Kidney Week 2018
    PR Newswire

    Regulus to Present Preclinical Data Supporting RGLS4326 as a Novel Therapeutic in Development for Autosomal Dominant Polycystic Kidney Disease at ASN's Kidney Week 2018

    LA JOLLA, Calif. , Oct. 22, 2018 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, ...

  • Regulus Regains Compliance with NASDAQ Listing Requirements
    PR Newswire

    Regulus Regains Compliance with NASDAQ Listing Requirements

    LA JOLLA, Calif. , Oct. 18, 2018 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, ...

  • Regulus Therapeutics Announces Reverse Stock Split
    PR Newswire

    Regulus Therapeutics Announces Reverse Stock Split

    The effective time of the reverse stock split was 5:00 p.m. ET on October 3, 2018.  The Company's shares will begin trading on a split-adjusted basis commencing upon market open on October 4, 2018. "Over the past several months, we have taken steps to reposition Regulus for long term sustainability.

  • Regulus to Participate in Fireside Chat at the Chardan Genetic Medicines Conference
    PR Newswire

    Regulus to Participate in Fireside Chat at the Chardan Genetic Medicines Conference

    Regulus Therapeutics Inc. (RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs.  Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field.  Regulus maintains its corporate headquarters in La Jolla, CA.  For more information, please visit http://www.regulusrx.com. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements.